Lecture 9: pancreatic islet hormones Flashcards
where does blood glucose come from?
- the food that we eat,
- stimulates the beta cells to release insulin
What is insulin?
- fuel storage hormone.
- its primary role is to decrease blood glucose and utilise this to store it.
What is the basic effect of insulin?
- increases glucose uptake into muscle and fat cells
- increases the synthesis of glycogen
- prevents the breakdown of glycogen
What is glycogen?
-our glucose storage format. This is stored in the liver for long term use
When is insulin secreted?
- when blood glucose levels increase.
- the b cells in the pancreas respond by releasing insulin both to absolute glucose levels and changes in blood glucose levels
What is the insulin profile of a normal person?
- there is always a baseline level of insulin being secreted (a baso semi state) so the body is never without any insulin release
- at the onset of glucose (due to eating a meal ) causes a very rapid insulin release. This reflects the release of stored insulin hormone in the beta cells and usually lasts 30 minutes.
- there is a secondary phase with a lower level of insulin release which is a bit more sustained. This reduces blood glucose back down to a steady state level
What does the second insulin release reflect?
the release of stored insulin and the reduction of release of new inulin
How is insulin secreted?
- ATP sensitive potassium channels normally let K+ outside the cell to maintain the resting potential
- glucose enters the B cells via the glut 2 transporter
- within the B cell we have increased glucose which is broken down by glucokinase to form ATP
- increased ATP shuts the ATP sensitive potassium channels by binding to them
- causes cell membrane to depolarise
- other channels present on B cells are also voltage dependent and wait for the B cell membrane to depolarise to allow an influx of calcium
- increased intracellular calcium stimulates the release of insulin from the B cell
Which receptors does insulin bind to?
Tyrosine kinase receptors
- these have two homodimer components
- insulin sits in the receptor as an agonist and phosphorylates the tyrosine kinase receptor which activates a number of secondary messenger pathways which in turn activate a number of things
What is the pathology of type 1 diabetes”
- type 1 is an autoimmune disease where the body’s immune system attacks and destroys B cells in the pancreas
- destruction can take several years to occur before clinical onset
- clinical onset tends to be very abrupt and sudden over a number of days
- eventually patient has no B cells left
What is the result of patients having no B cells?
- they cannot produce insulin so whenever they eat food, they run the risk of hyperglycaemia
- there is no insulin to utilise and store the blood glucose
- insulin is also involved in fatty acid synthesis which cannot occur if insulin is not produced. This results in ketosis or the formation of ketones which is a metabolic crisis
What happens if ketosis is not addressed?
patientscan slip into a coma and die
How is type I diabetes treated?
- can only provide the patient with insulin the body is not producing
- this is dependent on the administration of exogenous insulin to maintain their blood glucose levels and prevent the formation of ketones
Why have we changed from traditional bovine or porcine insulin to biotechnologically engineered inulin?
- the 1 or 2 amino acid difference between bovine or porcine insulin made it very poorly tolerated
- with genetic engineering, we can syntheticalyl form human insulin which looks and acts like the insulin the body would produce
How is insulin delivered?
- cannot be done orally as most are destroyed by proteases in the GIT before it is absorbed.
- the only way at the moment is via sub cut injection
- you can also obtain jet injection systems
- some patients have an insulin pump.
What are the developments in insulin therapy?
- now we have a range of different types of insulin with different duration of actions and rates of action
- humalog is rapid acting with short duration
- glargine is slow acting with a long duration of action
What is the advantage with the variation of insulin products?
-allows patient to mix and match depending on what they are doing in their lifestyle
What potential products could be produced using glucose responsive insulin release?
- we can have insulin being released by microgels in a controlled manner in response to glucose
- these injectable microgels contain insulin in nano-particles
- glucose comes in and is synthesised to glucomic acid which activates enzymes and releases insulin out into the capsule
- the amount of insulin release is affected by the amount of glucose entering the body
- this ensures that it is comparable to the blood glucose levels
What is Diabecell?
- Living cell technologies in auckland, NZ are conidering islet cell transplantation for type 1 diabetes agents
- porcine islet cells are being transplanted and these have already gone into phase III of clinical trials
- source is a population of pigs isolated on the auckland islands for several 100 years so they do not have diseases, thus we can provide completely pathogen free cells for transplantation into patients
What is the limitation with Dibecell porcine islet cell transplant therapy?
-we don’t know what causes type 1 diabetes so even if the transplantation of cells into the body was successful, these cells may also be killed off due to the autoimmune disease process
What is the pathology of type II diabetes?
- patient has insulin resistance and the body does not respond to the insulin released
- the baso insulin levels would be much higher
- there is nothing wrong with the B cells
What are the original theories regarding type II diabetes?
- insulin receptors deficient
- lack of numbers of insulin receptors
What are the recent theories regarding type II diabetes?
- something wrong with secondary messenger pathways in the middle
- body does not respond to insulin so blood glucose is not being taken up properly.
What are the classes of oral hypoglycaemic agents used to treat type II diabetes?
- sulfonylureas
- meglitinides
- biguanides
- alpha glycosidase inhibitors
- anti hyperglycaemic agents